Fujian Boro Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Boro R&D") is a drug marketing authorization holder enterprise dedicated to investment management of the pharmaceutical industry chain (including the entire drug life cycle such as CRO, CMO/CDMO, CSO, etc.). It is a wholly-owned subsidiary of Fujian Boro Pharmaceutical Co., Ltd., established in May 2016 with a registered capital of 100 million yuan. It has won the honorary titles of National High-tech Enterprise, Science and Technology-based Small and Medium-sized Enterprises, and Fujian Province Innovative Small and Medium-sized Enterprises.